UK-based CRO opens US headquarters

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/LewisTsePuiLung)
(Image: Getty/LewisTsePuiLung)

Related tags: Illingworth Research Group, Clinical research

Illingworth Research Group has accepted the challenge and set up shop in the US, the CEO says, as an increase in patient-focused protocol drives demand for the company’s mobile research nurse offering.

Headquartered in Macclesfield, UK, Illingworth Research Group has selected Denver, CO as its official US headquarters. Chief Operating Officer, Helen Springford, said the expansion has attracted new and existing clients with the company seeing “a rapid increase in activity stateside.”

The CRO currently has several studies ongoing at US-based sites, supported by clinical staff and research nurses in various states, Springford told us.

“This will be expanded as we win more and more work and we are actively advertising and onboarding nurses every day,”​ she said.

As for why Denver, Springford explained that a Denver based client wanted to work with one, global mobile research nursing (RN) provider.

“They said that they would support us setting up in the US as they like the way we work,”​ she added. “As we were offered two multinational mobile RN studies, we decided to accept the challenge and set up in the US.”

Springford said the company’s mobile RN offering is “extremely popular” at the moment with the increase in patient-focused study protocols.

“The demand is fairly uniform globally,”​ she explained, adding that the company has also recently opened in the Middle East, and “expect this to take off.”

“Our set up of employing the nurses ourselves rather than working with multiple vendors allows us to ensure they follow one global set of SOPs and are trained up and managed by Illingworth Research nursing project managers,”​ said Springford. “Having every single nurses, irrespective of where they are based, trained to the same standards ensures safety for patients and maximizes the quality of our work.”

Related topics: Clinical Development, Phase I-II

Related news

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more